NCT00823966 - Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

HIV-1 Infection

Interventions

DRUG

Rescriptor

"RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."